Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...

The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

Headline results from a REDEFINE-2 late-stage trial released last week showed that Novo's next-generation CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of ...